Necessity Really Is the Mother of Invention
In under two months, the ISCT managed to pull together a gamified virtual conference platform, allowing attendees to “walk up” and chat with exhibitors
James Strachan | | Quick Read
Last month, I attended my first virtual conference: the International Society for Cell and Gene Therapy’s annual meeting, which was supposed to take place in Paris. I must admit that I was skeptical. Like many of the “virtual” activities that have popped up in recent weeks, such as gallery and museum tours, I figured sitting at home (with yet more screen time) could never compare with the experience of actually walking the halls of the Louvre – or indeed an exhibition center. But I was pleasantly surprised (about the latter).
The ISCT meeting had a series of presentations and panel discussions conducted via video chat. A particular highlight for me was the showcase on COVID-19, notably Diane Kadidlo and Heidi Elmoazzen’s presentations on global supply chain issues – the topic of our June issue cover feature. According to Kadidlo, the University of Minnesota's cell therapy trials for cancer were put on hold and could only be approved on a case-by-case basis. And as Director of stem cells at Canadian Blood Services, Elmoazzen faced a number of challenges – cord blood collections ceasing, registry donors becoming unwilling to donate, issues transporting stem cells across borders – echoing the experience of our feature contributors.
But presentations are only one of the reasons we attend conferences – and arguably the easiest to replicate virtually. Creating a means of networking is the tricky part but, in just two months, the ISCT managed to put together a virtual platform that allowed us to “walk up” and chat with exhibitors – in over 30 languages via a translator function. And the whole thing was gamified, with points and prizes for interacting.
I wouldn’t say the experience was quite on a par with attending in person (it’s hard to replicate that one important chance encounter, an introduction from a colleague, or a night on the town...), but it was certainly valuable – especially for those who wouldn’t have been able to travel to Paris anyway.
Just as it seems the trend towards direct-to-patient clinical trials is unlikely to completely reverse when normality returns, I can’t see virtual conferences going away either.
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine